| Active, not recruiting | 2 | 385 | US | tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone | National Institute of Allergy and Infectious Diseases (NIAID), PPD | Heart Transplant | 04/25 | 04/25 | | |
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure |
|
|
| Recruiting | 2 | 150 | US | AB-1002, Gene Therapy, NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure | 10/26 | 12/30 | | |